Trials and Tribulations in Prostate Cancer: Xinlay Rejected by US FDA Committee

ISSN： 1176-3469

Source： Pharmaceutical & Diagnostic Innovation, Vol.3, Iss.10, 2005-01, pp. : 11-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rosiglitazone: Trials, Tribulations and Termination

By Krentz Andrew J.

Drugs, Vol. 71, Iss. 2, 2011-01 ,pp. : 123-130

Adis International

Access to resources Recommend Favorite

US FDA to review bladder cancer risks for pioglitazone

Reactions Weekly, Vol. 1, Iss. 1320, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The trials and tribulations of paediatric HIV research

Inpharma, Vol. 1, Iss. 1650, 2008-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Determinants of Accrual to Prostate Cancer Clinical Trials

By Moritz Sabine Robinson John W. White Leah J. Scott Ernst D. Venner Peter

UroOncology, Vol. 2, Iss. 4, 2002-01 ,pp. : 205-211

Ashgate Publishing Ltd

Access to resources Recommend Favorite

A US FDA advisory committee recommends that alosetron [`Lotronex'; GlaxoSmithKline] be reintroduced

Inpharma, Vol. 1, Iss. 1336, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite